XML 26 R12.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Property, Plant and Equipment | 12 Months Ended
--- | ---
Dec. 31, 2018
Property Plant And Equipment [Abstract] |
Property, Plant and Equipment | Note 4 — Property, Plant and Equipment Property, plant and equipment consists of the following (in thousands):
|  | December 31, |
|  | 2018 |  |  | 2017 |
Building and leasehold improvements |  | $ | 77,771 |  |  | $ | 81,444 |
Laboratory equipment |  |  | 33,806 |  |  |  | 31,214 |
Computers, furniture, and other |  |  | 31,354 |  |  |  | 27,800 |
Manufacturing equipment |  |  | 21,339 |  |  |  | 20,695 |
Depreciable property, plant and equipment at cost |  |  | 164,270 |  |  |  | 161,153 |
Less: accumulated depreciation |  |  | (120,507 | ) |  |  | (115,090 | )
Depreciable property, plant and equipment, net |  |  | 43,763 |  |  |  | 46,063 |
Construction-in-progress |  |  | 5,088 |  |  |  | 1,400 |
Property, plant and equipment, net |  | $ | 48,851 |  |  | $ | 47,463 |
Building and leasehold improvements include our manufacturing, research and development and administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment include assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets being built to enhance our manufacturing and research and development efforts. Depreciation and amortization expenses on property, plant and equipment for the years ended December 31, 2018, 2017, and 2016 was $8.8 million, $12.6 million, and $13.2 million, respectively. In November 2017, Bayer announced that the Phase 3 Amikacin Inhale clinical program did not meet its primary endpoint or key secondary endpoints and, in December 2017, Bayer terminated our related collaboration agreement. Under this collaboration, we were responsible for the development, manufacturing and supply of our proprietary nebulizer device included in the Amikacin product and had acquired specific manufacturing equipment for this purpose. As a result of the termination of the program, in the three months ended December 31, 2017, we expensed program specific manufacturing equipment with an original cost of $23.4 million and a net book value of $15.1 million. We completed the disposal of this equipment in the first quarter of 2018. In addition, in the three months ended December 31, 2017, we incurred approximately $0.9 million of other program termination costs related to our manufacturing obligations.

X
- References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -URI http://asc.fasb.org/topic&trid=2155823 + Details
Name: | us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration